山東新華製藥股份(00719.HK):獲得鹽酸伊伐佈雷定片藥品註冊證書
格隆匯6月30日丨山東新華製藥股份(00719.HK)發佈公吿,近日,公司的全資子公司山東淄博新達製藥有限公司(“新達製藥”)收到國家藥品監督管理局核准簽發的鹽酸伊伐佈雷定片《藥品註冊證書》,批准本品註冊。鹽酸伊伐佈雷定片適用於竇性心律且心率≥75 次/分鐘、伴有心臟收縮功能障礙的NYHAⅡ~Ⅳ級慢性心力衰竭患者,與標準治療包括β-受體阻滯劑聯合用藥,或者用於禁忌或不能耐受β-受體阻滯劑治療時。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.